SCHEMBL1687285

SCHEMBL1687285

COc1cccc(-c2cc3ccc(O)cc3c(=O)n2CC(=O)NC(C)(C)C)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MIF P14174 1/20 0.42
NR1I2 O75469 2/20 0.42
FPR1 P21462 1/20 0.42
FPR2 P25090 1/20 0.42
GAA P10253 2/20 0.41
ALDH1A1 P00352 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
MAPT P10636 3/20 0.41
TRPV1 Q8NER1 1/20 0.41
HSD17B10 Q99714 1/20 0.41
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
TP53 P04637 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
CYP2C19 P33261 1/20 0.40
KMT2A Q03164 1/20 0.40
AVPR1B P47901 5/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1687140 0.87 AVPR1B (0.51) MIFFPR1FPR2MAPTTRPV1
SCHEMBL1687409 0.86 AVPR1B (0.48) MIFNR1I2GAAALDH1A1HDAC6
SCHEMBL3136852 0.83 AVPR1B (0.57) AVPR1B
SCHEMBL1687126 0.83 NR1I2 (0.41) NR1I2GAAALDH1A1HDAC6KDM4E
SCHEMBL1687226 0.81 AVPR1B (0.62) AVPR1B
SCHEMBL1687256 0.81 AVPR1B (0.62) AVPR1B
SCHEMBL1687301 0.79 KDM4E (0.40) NR1I2GAAALDH1A1HDAC6KDM4E
SCHEMBL1687416 0.79 AVPR1B (0.53) AVPR1B
SCHEMBL14537320 0.77 FPR1 (0.51) FPR1FPR2GAAALDH1A1KDM4E
SCHEMBL1687230 0.74 AVPR1B (0.48) MAPTKMT2AAVPR1BCNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2066640-B1 2-(1-OXO-1H-ISOQUINOLIN-2-YL) ACETAMIDE DERIVATIVES ORGANON NV (NL) 2011-09-07 EP disclosed
US-7906504-B2 N-tert-Butyl-2-[3-(4-fluoro-3-methoxyphenyl)-1-oxo-7-(3-pyrrolidin-1-ylpropoxy)-1H-isoquinolin-2-yl]acetamide; 2-[3-(3-Chlorophenyl)-7-((S)-2-methyl-3-pyrrolidin-1-ylpropoxy)-1-oxo-1H-isoquinolin-2-yl]-N-isopropylacetamide; antidepressants; hypothalamo-pituitary-adrenal axis modulators N.V. ORGANON (NL) 2011-03-15 US disclosed
US-20080064678-A1 2-(1-OXO-1H-ISOQUINOLIN-2-YL)ACETAMIDE DERIVATIVES N.V. ORGANON (NL) 2008-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064678-A1 2-(1-OXO-1H-ISOQUINOLIN-2-YL)ACETAMIDE DERIVATIVES SULT2A1, ACAT2, HDAC6 MIF 2975/4885NR1I2 575/4885FPR1 2838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.